182 related articles for article (PubMed ID: 12443541)
1. Helios gene gun particle delivery for therapy of acid maltase deficiency.
Martiniuk F; Chen A; Mack A; Donnabella V; Slonim A; Bulone L; Arvanitopoulos E; Raben N; Plotz P; Rom WN
DNA Cell Biol; 2002 Oct; 21(10):717-25. PubMed ID: 12443541
[TBL] [Abstract][Full Text] [Related]
2. Adeno-associated virus-mediated transfer of human acid maltase gene results in a transient reduction of glycogen accumulation in muscle of Japanese quail with acid maltase deficiency.
Lin CY; Ho CH; Hsieh YH; Kikuchi T
Gene Ther; 2002 May; 9(9):554-63. PubMed ID: 11973631
[TBL] [Abstract][Full Text] [Related]
3. Correction of glycogen storage disease type II by enzyme replacement with a recombinant human acid maltase produced by over-expression in a CHO-DHFR(neg) cell line.
Martiniuk F; Chen A; Donnabella V; Arvanitopoulos E; Slonim AE; Raben N; Plotz P; Rom WN
Biochem Biophys Res Commun; 2000 Oct; 276(3):917-23. PubMed ID: 11027569
[TBL] [Abstract][Full Text] [Related]
4. Impact of humoral immune response on distribution and efficacy of recombinant adeno-associated virus-derived acid alpha-glucosidase in a model of glycogen storage disease type II.
Cresawn KO; Fraites TJ; Wasserfall C; Atkinson M; Lewis M; Porvasnik S; Liu C; Mah C; Byrne BJ
Hum Gene Ther; 2005 Jan; 16(1):68-80. PubMed ID: 15703490
[TBL] [Abstract][Full Text] [Related]
5. Glycogen storage in multiple muscles of old GSD-II mice can be rapidly cleared after a single intravenous injection with a modified adenoviral vector expressing hGAA.
Xu F; Ding E; Migone F; Serra D; Schneider A; Chen YT; Amalfitano A
J Gene Med; 2005 Feb; 7(2):171-8. PubMed ID: 15515143
[TBL] [Abstract][Full Text] [Related]
6. Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter.
Sun B; Zhang H; Franco LM; Brown T; Bird A; Schneider A; Koeberl DD
Mol Ther; 2005 Jun; 11(6):889-98. PubMed ID: 15922959
[TBL] [Abstract][Full Text] [Related]
7. Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectors.
Mah C; Cresawn KO; Fraites TJ; Pacak CA; Lewis MA; Zolotukhin I; Byrne BJ
Gene Ther; 2005 Sep; 12(18):1405-9. PubMed ID: 15920463
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II.
Sun B; Zhang H; Franco LM; Young SP; Schneider A; Bird A; Amalfitano A; Chen YT; Koeberl DD
Mol Ther; 2005 Jan; 11(1):57-65. PubMed ID: 15585406
[TBL] [Abstract][Full Text] [Related]
9. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.
Raben N; Fukuda T; Gilbert AL; de Jong D; Thurberg BL; Mattaliano RJ; Meikle P; Hopwood JJ; Nagashima K; Nagaraju K; Plotz PH
Mol Ther; 2005 Jan; 11(1):48-56. PubMed ID: 15585405
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy after [E1-, polymerase-] adenovirus-mediated transfer of human acid-alpha-glucosidase gene into glycogen storage disease type II knockout mice.
Ding EY; Hodges BL; Hu H; McVie-Wylie AJ; Serra D; Migone FK; Pressley D; Chen YT; Amalfitano A
Hum Gene Ther; 2001 May; 12(8):955-65. PubMed ID: 11387060
[TBL] [Abstract][Full Text] [Related]
11. Novel GAA sequence variant c.1211 A>G reduces enzyme activity but not protein expression in infantile and adult onset Pompe disease.
Nilsson MI; Kroos MA; Reuser AJ; Hatcher E; Akhtar M; McCready ME; Tarnopolsky MA
Gene; 2014 Mar; 537(1):41-5. PubMed ID: 24384324
[TBL] [Abstract][Full Text] [Related]
12. Complete correction of acid alpha-glucosidase deficiency in Pompe disease fibroblasts in vitro, and lysosomally targeted expression in neonatal rat cardiac and skeletal muscle.
Pauly DF; Johns DC; Matelis LA; Lawrence JH; Byrne BJ; Kessler PD
Gene Ther; 1998 Apr; 5(4):473-80. PubMed ID: 9614571
[TBL] [Abstract][Full Text] [Related]
13. Twenty-two novel mutations in the lysosomal alpha-glucosidase gene (GAA) underscore the genotype-phenotype correlation in glycogen storage disease type II.
Hermans MM; van Leenen D; Kroos MA; Beesley CE; Van Der Ploeg AT; Sakuraba H; Wevers R; Kleijer W; Michelakakis H; Kirk EP; Fletcher J; Bosshard N; Basel-Vanagaite L; Besley G; Reuser AJ
Hum Mutat; 2004 Jan; 23(1):47-56. PubMed ID: 14695532
[TBL] [Abstract][Full Text] [Related]
14. Enhanced efficacy of an AAV vector encoding chimeric, highly secreted acid alpha-glucosidase in glycogen storage disease type II.
Sun B; Zhang H; Benjamin DK; Brown T; Bird A; Young SP; McVie-Wylie A; Chen YT; Koeberl DD
Mol Ther; 2006 Dec; 14(6):822-30. PubMed ID: 16987711
[TBL] [Abstract][Full Text] [Related]
15. Intercellular transfer of the virally derived precursor form of acid alpha-glucosidase corrects the enzyme deficiency in inherited cardioskeletal myopathy Pompe disease.
Pauly DF; Fraites TJ; Toma C; Bayes HS; Huie ML; Hirschhorn R; Plotz PH; Raben N; Kessler PD; Byrne BJ
Hum Gene Ther; 2001 Mar; 12(5):527-38. PubMed ID: 11268285
[TBL] [Abstract][Full Text] [Related]
16. Genetic defects in patients with glycogenosis type II (acid maltase deficiency).
Raben N; Nichols RC; Boerkoel C; Plotz P
Muscle Nerve Suppl; 1995; 3():S70-4. PubMed ID: 7603531
[TBL] [Abstract][Full Text] [Related]
17. Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II.
Franco LM; Sun B; Yang X; Bird A; Zhang H; Schneider A; Brown T; Young SP; Clay TM; Amalfitano A; Chen YT; Koeberl DD
Mol Ther; 2005 Nov; 12(5):876-84. PubMed ID: 16005263
[TBL] [Abstract][Full Text] [Related]
18. Adenovirus-mediated transfer of the acid alpha-glucosidase gene into fibroblasts, myoblasts and myotubes from patients with glycogen storage disease type II leads to high level expression of enzyme and corrects glycogen accumulation.
Nicolino MP; Puech JP; Kremer EJ; Reuser AJ; Mbebi C; Verdière-Sahuqué M; Kahn A; Poenaru L
Hum Mol Genet; 1998 Oct; 7(11):1695-702. PubMed ID: 9736771
[TBL] [Abstract][Full Text] [Related]
19. [A retrospective study of six patients with late-onset Pompe disease].
Saux A; Laforet P; Pagès AM; Figarella-Branger D; Pellissier JF; Pagès M; Labauge P
Rev Neurol (Paris); 2008 Apr; 164(4):336-42. PubMed ID: 18439925
[TBL] [Abstract][Full Text] [Related]
20. Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors.
Fraites TJ; Schleissing MR; Shanely RA; Walter GA; Cloutier DA; Zolotukhin I; Pauly DF; Raben N; Plotz PH; Powers SK; Kessler PD; Byrne BJ
Mol Ther; 2002 May; 5(5 Pt 1):571-8. PubMed ID: 11991748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]